GlassScriptPhysician profile
Timothy Bradshaw
NPI 1457704256
$2,011.74
in general payments reported to CMS, 2019-2025
25 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $315 · 2021: $255 · 2022: $194 · 2023: $281 · 2024: $164 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $223.52 | 2019-2025 | |
| Alimera Sciences, INC. | $214.45 | 2021-2023 | Iluvien |
| Mallinckrodt Hospital Products INC. | $193.52 | 2020-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $170.21 | 2019-2020 | |
| Dompe US, INC. | $168.69 | 2019-2025 | Oxervate |
| Mallinckrodt Enterprises LLC | $135.33 | 2019 | |
| Allergan, INC. | $122.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $111.88 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $97.48 | 2020-2022 | |
| Alcon Vision LLC | $85.75 | 2022-2023 | Clareon, Hydrus Microstent, Total30 |
| Horizon Therapeutics Plc | $85.74 | 2019-2022 | |
| Sight Sciences, INC. | $62.52 | 2021-2024 | Tearcare System |
| Rxsight INC | $60.91 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Rayner Intraocular Lenses Limited | $60.25 | 2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Oyster Point Pharma, INC. | $30.32 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $25.41 | 2024 | Myday Contact Lens |
| Regeneron Healthcare Solutions, INC. | $21.88 | 2021 | |
| Abbvie INC. | $21.10 | 2024 | |
| Shire North American Group INC | $21.03 | 2019 | |
| Spark Therapeutics, INC. | $19.44 | 2021 | |
| Apellis Pharmaceuticals, INC. | $19.40 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $17.98 | 2025 | Scoutpro Osmolarity System |
| Thea Pharma INC. | $17.11 | 2024 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $15.18 | 2024 | |
| Visioneering Technologies, INC. | $10.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Bradshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.